Non-small-cell lung cancer: molecular targeted therapy and personalized medicine – drug resistance, mechanisms, and strategies

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin201262102922237781
   PubMed Web of Science ®Google Scholar
• OkuboKMarkEJFliederDBronchoalveolar carcinoma: clinical, radiologic, and pathologic factors and survivalJ Thorac Cardiovasc Surg199911870270910504637
   PubMed Web of Science ®Google Scholar
• RazDJHeBRosellRJablonsDMCurrent concepts in bronchioloal-veolar carcinoma biologyClin Cancer Res2006123698370416778095
   PubMed Web of Science ®Google Scholar
• SiegelRDeSantisCVirgoKCancer treatment and survivorship statistics, 2012CA Cancer J Clin20126222024122700443
   PubMed Web of Science ®Google Scholar
• KhuriFRHerbstRSFossellaFVEmerging therapies in non-small-cell lung cancerAnn Oncol20011273974411484947
   PubMed Web of Science ®Google Scholar
• WeinsteinIBCancer. Addiction to oncogenes – the Achilles heal of cancerScience2002297636412098689
   PubMed Web of Science ®Google Scholar
• HabeckMFDA licences imatinib mesylate for CMLLancet Oncol20023611905608
   PubMed Web of Science ®Google Scholar
• CarpenterGCohenSEpidermal growth factorJ Biol Chem1990265770977122186024
   PubMed Web of Science ®Google Scholar
• CohenMHWilliamsGASridharaRChenGPazdurRFDA drug approval summary: gefitinib (ZD1839) (Iressa) tabletsOncologist2003830330612897327
   PubMed Web of Science ®Google Scholar
• CohenMHJohnsonJRChenYFSridharaRPazdurRFDA drug approval summary: erlotinib (Tarceva) tabletsOncologist20051046146616079312
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet20053661527153716257339
   PubMed Web of Science ®Google Scholar
• ShepherdFARodrigues PereiraJCiuleanuTErlotinib in previously treated non-small-cell lung cancerN Engl J Med200535312313216014882
   PubMed Web of Science ®Google Scholar
• GazdarAFActivating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene200928Suppl 1S24S3119680293
   PubMed Web of Science ®Google Scholar
• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• MarchettiAMartellaCFelicioniLEGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatmentJ Clin Oncol20052385786515681531
   PubMed Web of Science ®Google Scholar
• PaezJGJännePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience20043041497150015118125
   PubMed Web of Science ®Google Scholar
• WuYLZhongWZLiLYEpidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland ChinaJ Thorac Oncol2007243043917473659
   PubMed Web of Science ®Google Scholar
• ShaoYYLinCCYangCHGefitinib or erlotinib in the treatment of advanced non-small cell lung cancerDiscov Med2010953854520587343
   PubMed Web of Science ®Google Scholar
• CostaECTaronMQueraltCDifferential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC studyJ Clin Oncol201230Suppl7540
   Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• OxnardGRArcilaMESimaCSAcquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutationClin Cancer Res2011171616162221135146
   PubMed Web of Science ®Google Scholar
• RosellRMoranTQueraltCScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med200936195896719692684
   PubMed Web of Science ®Google Scholar
• YunCHMengwasserKETomsAVThe T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProc Natl Acad Sci USA20081052070207518227510
   PubMed Web of Science ®Google Scholar
• PaoWMillerVAPolitiKAAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med20052e7315737014
   PubMed Web of Science ®Google Scholar
• KosakaTYatabeYEndohHAnalysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinibClin Cancer Res2006125764576917020982
   PubMed Web of Science ®Google Scholar
• HammermanPSJannePAJohnsonBEResistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerClin Cancer Res2009157502750920008850
   PubMed Web of Science ®Google Scholar
• SudaKMizuuchiHMaeharaYMitsudomiTAcquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destinyCancer Metastasis Rev20123180781422736441
   PubMed Web of Science ®Google Scholar
• EngelmanJAZejnullahuKMitsudomiTMET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingScience20073161039104317463250
   PubMed Web of Science ®Google Scholar
• CappuzzoFJännePASkokanMMET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patientsAnn Oncol20092029830418836087
   PubMed Web of Science ®Google Scholar
• KosakaTYamakiEMogiAKuwanoHMechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancerJ Biomed Biotechnol2011201116521421687596
   PubMed Web of Science ®Google Scholar
• SosMLKokerMWeirBAPTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRCancer Res2009693256326119351834
   PubMed Web of Science ®Google Scholar
• ThomsonSBuckEPettiFEpithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibitionCancer Res2005659455946216230409
   PubMed Web of Science ®Google Scholar
• ChangTHTsaiMFSuKYSlug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitorAm J Respir Crit Care Med20111831071107921037017
   PubMed Web of Science ®Google Scholar
• WinnRATuderRM“Un-slugging” resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapyAm J Respir Crit Care Med201118397097221498821
   PubMed Web of Science ®Google Scholar
• NgKPHillmerAMChuahCTA common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancerNat Med20121852152822426421
   PubMed Web of Science ®Google Scholar
• PaoWWangTYRielyGJKRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinibPLoS Med20052e1715696205
   PubMed Web of Science ®Google Scholar
• MassarelliEVarella-GarciaMTangXKRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerClin Cancer Res2007132890289617504988
   PubMed Web of Science ®Google Scholar
• SchmidKOehlNWrbaFPirkerRPirkerCFilipitsMEGFR/ KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastasesClin Cancer Res2009154554456019584155
   PubMed Web of Science ®Google Scholar
• ShigematsuHLinLTakahashiTClinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancersJ Natl Cancer Inst20059733934615741570
   PubMed Web of Science ®Google Scholar
• KrisMGJohnsonBEKwiatkowskiIdentification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC)J Clin Oncol201129SupplCRA7506
   Google Scholar
• BrokerLEGiacconeGThe role of new agents in the treatment of non-small cell lung cancerEur J Cancer2002382347236112460778
   PubMed Web of Science ®Google Scholar
• EngelmanJAChenLTanXEffective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNat Med2008141351135619029981
   PubMed Web of Science ®Google Scholar
• JännePAShawATPereiraJREfficacy and patient (pt)-reported outcomes (PROs) with selumetinib (AZD6244, ARRY-142866; SEL) + docetaxel (Doc) in KRAS-mutant advanced non-small cell lung cancer (NSCLC): a randomized, phase II trialAnn Oncol201223Suppl 91233PD
   Google Scholar
• RamalingamSBelaniCPRecent advances in targeted therapy for non-small cell lung cancerExpert Opin Ther Targets20071124525717227238
   PubMed Web of Science ®Google Scholar
• RosellRRobinetGSzczesnaARandomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/ vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancerAnn Oncol20081936236917947225
   PubMed Web of Science ®Google Scholar
• PirkerRPereiraJRSzczesnaACetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialLancet20093731525153119410716
   PubMed Web of Science ®Google Scholar
• HannaNHDahlbergSEKolesarJThree-arm randomized phase II study of carboplatin (C) and paclitaxel (P) in combination with cetuximab (CET), IMC-A12, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: an Eastern Cooperative Oncology Group (ECOG) study (E4508)J Clin Oncol201230Suppl7516
   Google Scholar
• GreillierLMartel-LafayIArpinDA randomised phase II study of cetuximab (c) in combination with two cisplatin-based concurrent chemoradiotherapy regimens in patients (pts) with stage III non-small cell lung cancer (NSCLC). Final results of the GFPC 08-03 trialPaper presented at the 37th European Society for Medical Oncology (ESMO) CongressSeptember 28–October 2, 2012Vienna, Austria
   Google Scholar
• GridelliCMaionePFerraraMLRossiACetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancerOncologist20091460161119482958
   PubMed Web of Science ®Google Scholar
• MaPCPersonalized targeted therapy in advanced non-small cell lung cancerCleve Clin J Med201279Suppl 1eS56eS6022614968
   PubMedGoogle Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature200744856156617625570
   PubMed Web of Science ®Google Scholar
• KoivunenJPMermelCZejnullahuKEML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancerClin Cancer Res2008144275428318594010
   PubMed Web of Science ®Google Scholar
• KwakELBangYJCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med20103631693170320979469
   PubMed Web of Science ®Google Scholar
• FordePMRudinCMCrizotinib in the treatment of non-small-cell lung cancerExpert Opin Pharmacother2012131195120122594847
   PubMed Web of Science ®Google Scholar
• GalettaDRossiAPiscontiSColucciGThe emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancerExpert Opin Ther Targets201216Suppl 2S45S5422443113
   PubMed Web of Science ®Google Scholar
• KimuraHALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activityLung Cancer201275667221757253
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLTogashiYKIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancerClin Cancer Res2009153143314919383809
   PubMed Web of Science ®Google Scholar
• TogashiYSodaMSakataSKLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue onlyPLoS One20127e3132322347464
   PubMed Web of Science ®Google Scholar
• WeickhardtAJRothmanMSSalian-MehtaSRapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancerCancer20121185302530922488744
   PubMed Web of Science ®Google Scholar
• SchnellPSaffermanAZBartlettCHTangYWilnerKDClinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK+) advanced non-small cell lung cancer (NSCLC)J Clin Oncol201230Suppl7598
   Google Scholar
• ZhangSWangFKeatsJCrizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screenChem Biol Drug Des201178999100522034911
   PubMed Web of Science ®Google Scholar
• DoebeleRCPillingABAisnerDLMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancerClin Cancer Res2012181472148222235099
   PubMed Web of Science ®Google Scholar
• KatayamaRShawATKhanTMMechanisms of acquired crizotinib resistance in ALK-rearranged lung cancersSci Transl Med20124120ra17
   PubMed Web of Science ®Google Scholar
• CamidgeDRDoebeleRCTreating ALK-positive lung cancer – early successes and future challengesNat Rev Clin Oncol2012926827722473102
   PubMed Web of Science ®Google Scholar
• ChenZSasakiTTanXInhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogeneCancer Res2010709827983620952506
   PubMed Web of Science ®Google Scholar
• KatayamaRKhanTMBenesCTherapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Natl Acad Sci USA20111087535754021502504
   PubMed Web of Science ®Google Scholar
• GaronEBMoranTBarlesiFPhase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC)J Clin Oncol201230Suppl7543
   Google Scholar
• SasakiTJannePANew strategies for treatment of ALK-rearranged non-small cell lung cancersClin Cancer Res2011177213721822010214
   PubMed Web of Science ®Google Scholar
• HeuckmannJMHölzelMSosMLALK mutations conferring differential resistance to structurally diverse ALK inhibitorsClin Cancer Res2011177394740121948233
   PubMed Web of Science ®Google Scholar
• HanahanDWeinbergRAThe hallmarks of cancerCell2000100577010647931
   PubMed Web of Science ®Google Scholar
• FolkmanJWhat is the evidence that tumors are angiogenesis dependent?J Natl Cancer Inst199082461688381
   PubMed Web of Science ®Google Scholar
• ReckMGatzemeierUTargeted therapies: thalidomide in lung cancer therapy – what have we learned?Nat Rev Clin Oncol2010713413520190796
   PubMed Web of Science ®Google Scholar
• HoangTDahlbergSESchillerJHRandomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 studyJ Clin Oncol20123061662222271472
   PubMed Web of Science ®Google Scholar
• YangJCHaworthLSherryRMA randomized trial of bevacizumab, n anti-vascular endothelial growth factor antibody, for metastatic renal cancerN Engl J Med200334942743412890841
   PubMed Web of Science ®Google Scholar
• KindlerHLShulmanKLMetastatic colorectal cancerCurr Treat Options Oncol2001245947112057092
   PubMedGoogle Scholar
• AzimHAJrGantiAKTargeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?Cancer Treat Rev20063263063617034953
   PubMed Web of Science ®Google Scholar
• LaskinJJSandlerABFirst-line treatment for advanced non-small-cell lung cancerOncology (Williston Park)20051916711676 discussion1678168016425521
   PubMed Web of Science ®Google Scholar
• DempkeWCSutoTReckMTargeted therapies for non-small cell lung cancerLung Cancer20106725727419914732
   PubMed Web of Science ®Google Scholar
• StevensonJPLangerCJSomerRAPhase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancerCancer20121185580558722544579
   PubMed Web of Science ®Google Scholar
• RoehrBBevacizumab as adjuvant therapy for lung cancer does not help patients over 65BMJ2012344e285522517975
   PubMed Web of Science ®Google Scholar
• DasanuCABevacizumab in lung cancer: lackluster performance and unjustified expense?J Oncol Pharm Pract20121838138222777997
   PubMedGoogle Scholar
• OhyanagiFTanimotoASakataniTPhase II trial of bevacizumab plus docetaxel in patients with previously treated nonsquamous non-small cell lung cancerJ Clin Oncol201230Supple18004
   Google Scholar
• RamalingamSSOwonikokoTKKhuriFRLung cancer: new biological insights and recent therapeutic advancesCA Cancer J Clin2011619111221303969
   PubMed Web of Science ®Google Scholar
• GridelliCMaionePDel GaizoFSorafenib and sunitinib in the treatment of advanced non-small cell lung cancerOncologist20071219120017296815
   PubMed Web of Science ®Google Scholar
• TanEHGossGDSalgiaRPhase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancerJ Thorac Oncol201161418142521597387
   PubMed Web of Science ®Google Scholar
• RamalingamSSShtivelbandMSooRARandomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous NSCLCJ Clin Oncol201230Suppl7512
   Google Scholar
• Paz-AresLGBiesmaBHeigenerDPhase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancerJ Clin Oncol2012303084309222851564
   PubMed Web of Science ®Google Scholar
• BriaEPilottoSTortoraGSorafenib for lung cancer: is the “Battle” still open?Expert Opin Investig Drugs20122114451448
   PubMed Web of Science ®Google Scholar
• ZhangJGoldKAKimESorafenib in non-small cell lung cancerExpert Opin Investig Drugs20122114171426
   PubMed Web of Science ®Google Scholar
• NealJWSequistLVExciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and HhCurr Treat Options Oncol201011364420676809
   PubMed Web of Science ®Google Scholar
• OwonikokoTKRamalingamSSKanterewiczBBaliusTEBelaniCPHershbergerPAVorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cellsInt J Cancer201012674375519621389
   PubMed Web of Science ®Google Scholar
• LiCTHsiaoYMWuTCLinYWYehKTKoJLVorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cellsJ Cell Biochem20111123044305321678477
   PubMed Web of Science ®Google Scholar
• OubanAMuracaPYeatmanTCoppolaDExpression and distribution of insulin-like growth factor-1 receptor in human carcinomasHum Pathol20033480380814506643
   PubMed Web of Science ®Google Scholar
• RowinskyEKYoussoufianHTonraJRSolomonPBurtrumDLudwigDLIMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptorClin Cancer Res2007135549s5555s17875788
   PubMed Web of Science ®Google Scholar
• McKianKPHaluskaPCixutumumabExpert Opin Investig Drugs20091810251033
   PubMed Web of Science ®Google Scholar
• WeickhardtADoebeleROtonAA phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancerJ Thorac Oncol2012741942622237261
   PubMed Web of Science ®Google Scholar
• ScagliottiGVNovelloSThe role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumorsCancer Treat Rev20123829230221907495
   PubMed Web of Science ®Google Scholar
• KarpDDPaz-AresLGNovelloSPhase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancerJ Clin Oncol2009272516252219380445
   PubMed Web of Science ®Google Scholar
• GualbertoAHixonMLKarpDDPre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumabBr J Cancer2011104687421102589
   PubMed Web of Science ®Google Scholar
• KrysanKMerchantFHZhuLCOX-2-dependent stabilization of survivin in non-small cell lung cancerFASEB J20041820620814597555
   PubMed Web of Science ®Google Scholar
• LiFLiuYChenHEGFR and COX-2 protein expression in non-small cell lung cancer and the correlation with clinical featuresJ Exp Clin Cancer Res2011302721385353
   PubMed Web of Science ®Google Scholar
• TennisMAVanscoykMKeithRLWinnRAThe role of prostacyclin in lung cancerTransl Res2010155576120129485
   PubMed Web of Science ®Google Scholar
• MutterRLuBCarboneDPA phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancerClin Cancer Res2009152158216519276291
   PubMed Web of Science ®Google Scholar
• MaoJTRothMDFishbeinMCLung cancer chemoprevention with celecoxib in former smokersCancer Prev Res (Phila)2011498499321733822
   PubMed Web of Science ®Google Scholar
• CathcartMCGraySGBairdAMProstacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancerCancer20111175121513221523772
   PubMed Web of Science ®Google Scholar
• KeithRLKaroorVMozerABHudishTMLeMMillerYEChemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpressionLung Cancer201070374220116128
   PubMed Web of Science ®Google Scholar
• KeithRLMillerYEHoshikawaYManipulation of pulmonary prostacyclin synthase expression prevents murine lung cancerCancer Res20026273474011830527
   PubMed Web of Science ®Google Scholar
• NemenoffRMeyerAMHudishTMProstacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator – activated receptor gammaCancer Prev Res (Phila)2008134935619138979
   PubMed Web of Science ®Google Scholar
• HazraSPeeblesKASharmaSMaoJTDubinettSMThe role of PPARgamma in the cyclooxygenase pathway in lung cancerPPAR Res2008200879056818769553
   PubMed Web of Science ®Google Scholar
• SasakiHTanahashiMYukiueHDecreased perioxisome proliferator-activated receptor gamma gene expression was correlated with poor prognosis in patients with lung cancerLung Cancer200236717611891036
   PubMed Web of Science ®Google Scholar
• GovindarajanRRatnasingheLSimmonsDLThiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetesJ Clin Oncol2007251476148117442990
   PubMed Web of Science ®Google Scholar
• WangMZhaoJZhangLMCombined erlotinib and cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancerJ Cancer Res Clin Oncol20121382069207722821179
   PubMed Web of Science ®Google Scholar
• HauraEBTanvetyanonTChiapporiAPhase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancerJ Clin Oncol2010281387139420142592
   PubMed Web of Science ®Google Scholar
• YamamotoNMurakamiHTakahashiTFinal results of a Japanese phase 1 trial evaluating a c-met inhibitor tivantinib in combination with an EGFR inhibitor erlotinib in advanced/metastatic non-small cell lung cancer (ARQ 197-003/005 study)Ann Oncol201223Suppl 9ix424
   Google Scholar
• GridelliCMorgilloFFavarettoASorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II studyAnn Oncol2011221528153421212155
   PubMed Web of Science ®Google Scholar
• ScagliottiGVKrzakowskiMSzczesnaASunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trialJ Clin Oncol2012302070207822564989
   PubMed Web of Science ®Google Scholar
• Van ScoykMRandallJSergewAWilliamsLMTennisMWinnRAWnt signaling pathway and lung diseaseTransl Res200815117518018355764
   PubMed Web of Science ®Google Scholar
• TennisMVan ScoykMWinnRARole of the wnt signaling pathway and lung cancerJ Thorac Oncol2007288989217909349
   PubMed Web of Science ®Google Scholar
• Pacheco-PinedoECDurhamACStewartKMWnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epitheliumJ Clin Invest20111211935194521490395
   PubMed Web of Science ®Google Scholar
• KimJYouLXuZWnt inhibitory factor inhibits lung cancer cell growthJ Thorac Cardiovasc Surg200713373373717320573
   PubMed Web of Science ®Google Scholar
• YaoHAshiharaEStrovelJWAV-65, a novel Wnt/beta-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse modelBlood Cancer J20111e4322829079
   PubMedGoogle Scholar
• WinnRAMarekLHanSYRestoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiationJ Biol Chem2005280196251963415705594
   PubMed Web of Science ®Google Scholar
• TennisMAVan ScoykMMFreemanSVVandervestKMNemenoffRAWinnRASprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancerMol Cancer Res2010883384320501643
   PubMed Web of Science ®Google Scholar
• TennisMAVanscoykMMWilsonLAKelleyNWinnRAMethylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancerPLoS One20127e3292122403725
   PubMed Web of Science ®Google Scholar
• KaukinenSYlitaloPPessiTVapaataloHHemodynamic effects of iloprost, a prostacyclin analogClin Pharmacol Ther1984364644696206978
   PubMed Web of Science ®Google Scholar
• TennisMAVan ScoykMHeasleyLEProstacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1Neoplasia20101224425320234818
   PubMed Web of Science ®Google Scholar
• ZhangSZhangHYangXDetection of EGFR and KRAS somatic mutations in tumor tissue and peripheral blood by a liquidchip technology for patients with advanced non-small cell lung cancerJ Clin Oncol201230Supple18142
   Google Scholar
• WangKStephensPYelenskyRFrequency of actionable genomic alterations in early-stage lung adenocarcinoma (LA) detected by next-generation sequencing (NGS)J Clin Oncol201230Supple17541
   Google Scholar
• PeiferMFernández-CuestaLSosMLIntegrative genome analyses identify key somatic driver mutations of small-cell lung cancerNat Genet2012441104111022941188
   PubMed Web of Science ®Google Scholar
• RudinCMDurinckSStawiskiEWComprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancerNat Genet2012441111111622941189
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research NetworkComprehensive genomic characterization of squamous cell lung cancersNature201248951952522960745
   PubMed Web of Science ®Google Scholar